Valuation: Plus Therapeutics, Inc.

Market Cap 26.36M 23.15M 21.53M 19.76M 37.13M 2.54B 37.7M 256M 99.9M 1.25B 98.96M 96.83M 4.32B P/E 2026 *
-0.98x
P/E 2027 * -1.6x
Enterprise Value 26.36M 23.15M 21.53M 19.76M 37.13M 2.54B 37.7M 256M 99.9M 1.25B 98.96M 96.83M 4.32B EV / Sales 2026 *
4.19x
EV / Sales 2027 * 1.38x
Free-Float
98.02%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Plus Therapeutics, Inc.

1 day+1.32%
1 week+2.41%
Current month-12.36%
1 month-8.81%
3 months-41.97%
6 months-40.11%
Current year-70.10%
1 week 3.72
Extreme 3.72
4.08
1 month 3.58
Extreme 3.58
4.51
Current year 2.9
Extreme 2.9
15.32
1 year 2.9
Extreme 2.9
23.42
3 years 2.9
Extreme 2.9
80.25
5 years 2.9
Extreme 2.9
870
10 years 2.9
Extreme 2.9
429,377.68
Manager TitleAgeSince
Chief Executive Officer 64 02/04/2014
Director of Finance/CFO 52 06/02/2020
Chief Tech/Sci/R&D Officer - 21/10/2025
Director TitleAgeSince
Director/Board Member 64 01/10/2002
Chairman 77 25/01/2018
Director/Board Member 66 01/01/2020
Date Insider Type Main position Quantity % Market Cap.
1/7/26 Fiscal year

Chief Financial Officer

5,970 0.0870%
1/7/26 Fiscal year

Chief Executive Officer

32,878 0.4791%
1/7/26 Fiscal year

Chairman

1,844 0.0269%
Change 5-day change 1-year change 3-year change Capi.($)
+1.32%+2.41%-71.08%-94.24% 26.36M
+1.07%-3.49%-3.35%+11.75% 46.86B
+0.25%+1.65%+399.22%+647.65% 40.23B
-0.27%+4.45%+11.81%+60.81% 36.23B
+0.35%+0.87%+4.46%-10.31% 34.72B
+3.14%+1.02%+4.76%+43.00% 27.89B
-0.73%+11.84%+34.39%+134.44% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%-3.43%+9.10% 13.12B
-2.68%-2.49%-11.36%-34.51% 12.7B
Average +0.33%+0.99%+40.60%+85.30% 24.53B
Weighted average by Cap. +0.48%+0.91%+74.40%+138.19%

Financials

2026 *2027 *
Net sales 6.3M 5.53M 5.14M 4.72M 8.87M 606M 9M 61.06M 23.86M 298M 23.63M 23.12M 1.03B 19.14M 16.81M 15.63M 14.35M 26.96M 1.84B 27.37M 186M 72.53M 906M 71.86M 70.31M 3.13B
Net income -26.8M -23.54M -21.89M -20.09M -37.74M -2.58B -38.32M -260M -102M -1.27B -101M -98.44M -4.39B -18.45M -16.21M -15.07M -13.83M -25.99M -1.78B -26.39M -179M -69.93M -874M -69.28M -67.79M -3.02B
Net Debt - -
Logo Plus Therapeutics, Inc.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
Employees
28
Date Price Change Volume
24/07/26 US$3.830 +1.32% 67,553
23/07/26 US$3.780 -1.05% 63,801
22/07/26 US$3.820 -2.55% 57,632
21/07/26 US$3.920 +2.35% 75,574
20/07/26 US$3.830 +2.41% 70,625
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.830USD
Average target price
36.00USD
Spread / Average Target
+839.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PSTV Stock